160 related articles for article (PubMed ID: 27519972)
1. Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells -Implications for myeloma bone disease.
Dotterweich J; Schlegelmilch K; Keller A; Geyer B; Schneider D; Zeck S; Tower RJ; Ebert R; Jakob F; Schütze N
Bone; 2016 Dec; 93():155-166. PubMed ID: 27519972
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.
Garcia-Gomez A; De Las Rivas J; Ocio EM; Díaz-Rodríguez E; Montero JC; Martín M; Blanco JF; Sanchez-Guijo FM; Pandiella A; San Miguel JF; Garayoa M
Oncotarget; 2014 Sep; 5(18):8284-305. PubMed ID: 25268740
[TBL] [Abstract][Full Text] [Related]
3. The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma.
Kassen D; Moore S; Percy L; Herledan G; Bounds D; Rodriguez-Justo M; Croucher P; Yong K
Br J Haematol; 2014 Oct; 167(2):194-206. PubMed ID: 25079197
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma cells promote migration of bone marrow mesenchymal stem cells by altering their translation initiation.
Dabbah M; Attar-Schneider O; Zismanov V; Tartakover Matalon S; Lishner M; Drucker L
J Leukoc Biol; 2016 Oct; 100(4):761-770. PubMed ID: 27272311
[TBL] [Abstract][Full Text] [Related]
5. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.
Bolomsky A; Hose D; Schreder M; Seckinger A; Lipp S; Klein B; Heintel D; Ludwig H; Zojer N
J Hematol Oncol; 2015 Feb; 8():10. PubMed ID: 25887188
[TBL] [Abstract][Full Text] [Related]
6. Cancellous bone allograft seeded with human mesenchymal stromal cells: a potential good manufacturing practice-grade tool for the regeneration of bone defects.
Stiehler M; Seib FP; Rauh J; Goedecke A; Werner C; Bornhäuser M; Günther KP; Bernstein P
Cytotherapy; 2010 Sep; 12(5):658-68. PubMed ID: 20429788
[TBL] [Abstract][Full Text] [Related]
7. Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease.
Garcia-Gomez A; Li T; de la Calle-Fabregat C; Rodríguez-Ubreva J; Ciudad L; Català-Moll F; Godoy-Tena G; Martín-Sánchez M; San-Segundo L; Muntión S; Morales X; Ortiz-de-Solórzano C; Oyarzabal J; San José-Enériz E; Esteller M; Agirre X; Prosper F; Garayoa M; Ballestar E
Nat Commun; 2021 Jan; 12(1):421. PubMed ID: 33462210
[TBL] [Abstract][Full Text] [Related]
8. Differential long noncoding RNA/mRNA expression profiling and functional network analysis during osteogenic differentiation of human bone marrow mesenchymal stem cells.
Zhang W; Dong R; Diao S; Du J; Fan Z; Wang F
Stem Cell Res Ther; 2017 Feb; 8(1):30. PubMed ID: 28173844
[TBL] [Abstract][Full Text] [Related]
9. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.
Bolzoni M; Donofrio G; Storti P; Guasco D; Toscani D; Lazzaretti M; Bonomini S; Agnelli L; Capocefalo A; Dalla Palma B; Neri A; Nicolini F; Lisignoli G; Russo F; Colla S; Aversa F; Giuliani N
Leukemia; 2013 Feb; 27(2):451-63. PubMed ID: 22781592
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of lncRNA MEG3 Promotes Osteogenic Differentiation of Mesenchymal Stem Cells From Multiple Myeloma Patients By Targeting BMP4 Transcription.
Zhuang W; Ge X; Yang S; Huang M; Zhuang W; Chen P; Zhang X; Fu J; Qu J; Li B
Stem Cells; 2015 Jun; 33(6):1985-97. PubMed ID: 25753650
[TBL] [Abstract][Full Text] [Related]
11. Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma.
Li B; Shi M; Li J; Zhang H; Chen B; Chen L; Gao W; Giuliani N; Zhao RC
Stem Cells Dev; 2007 Dec; 16(6):921-30. PubMed ID: 17927494
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth.
Li X; Ling W; Khan S; Yaccoby S
J Bone Miner Res; 2012 Aug; 27(8):1635-48. PubMed ID: 22460389
[TBL] [Abstract][Full Text] [Related]
13. Tumor-host cell interactions in the bone disease of myeloma.
Fowler JA; Edwards CM; Croucher PI
Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
[TBL] [Abstract][Full Text] [Related]
14. Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival.
Lo CH; Shay G; McGuire JJ; Li T; Shain KH; Choi JY; Fuerst R; Roush WR; Knapinska AM; Fields GB; Lynch CC
Cancer Res; 2021 May; 81(9):2415-2428. PubMed ID: 33526510
[TBL] [Abstract][Full Text] [Related]
15. Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets.
Giuliani N; Mangoni M; Rizzoli V
Exp Hematol; 2009 Aug; 37(8):879-86. PubMed ID: 19446662
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.
Yaccoby S; Wezeman MJ; Zangari M; Walker R; Cottler-Fox M; Gaddy D; Ling W; Saha R; Barlogie B; Tricot G; Epstein J
Haematologica; 2006 Feb; 91(2):192-9. PubMed ID: 16461303
[TBL] [Abstract][Full Text] [Related]
17. Modeling Myeloma Dissemination In Vitro with hMSC-interacting Subpopulations of INA-6 Cells and Their Aggregation/Detachment Dynamics.
Kuric M; Beck S; Schneider D; Rindt W; Evers M; Meißner-Weigl J; Zeck S; Krug M; Herrmann M; Hartmann TN; Leich E; Rudert M; Docheva D; Seckinger A; Hose D; Jundt F; Ebert R
Cancer Res Commun; 2024 Apr; 4(4):1150-1164. PubMed ID: 38598843
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma cells modify VEGF/IL-6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR-223.
Berenstein R; Nogai A; Waechter M; Blau O; Kuehnel A; Schmidt-Hieber M; Kunitz A; Pezzutto A; Dörken B; Blau IW
Mol Carcinog; 2016 Dec; 55(12):1927-1939. PubMed ID: 27023728
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S
Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
